ESC 365 - FXa promotes endothelial dysfunction and pro-remodeling responses in atrial endothelial cells involving PAR1 and 2 and AT1R/NADPH oxidase/SGLT1/2 pro-oxidant pathways

HFA Premium Access

FXa promotes endothelial dysfunction and pro-remodeling responses in atrial endothelial cells involving PAR1 and 2 and AT1R/NADPH oxidase/SGLT1/2 pro-oxidant pathways

Session: New therapeutic approaches for heart failure

Topic: Drugs, Drug Targets

Speaker: Doctor W. Fakih (Strasbourg, FR)

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Doctor Walaa Fakih

INSERM, University of Strasbourg, CRBS, Strasbourg (France)

1 follower

4 more presentations in this session

Repurposing of glatiramer acetate to treat cardiac ischemia

Speaker: Doctor G. Aviel (Rehovot, IL)

Repeated low doses of doxorubicin induce senescence and functional decline in dyn-EHTs which can be rescued using senomorphics.

Speaker: Ms A. Linders (Groningen, NL)

Living myocardial slices for the study of nucleic acid-based therapies

Speaker: Doctor R. Nunez-Toldra (London, GB)

Identification and characterization of small-molecule ERBB4 agonists as a treatment for heart failure

Speaker: Miss E. Feyen (Antwerp, BE)

Access the full session

New therapeutic approaches for heart failure

Speakers: Doctor W. Fakih, Doctor G. Aviel, Ms A. Linders, Doctor R. Nunez-Toldra, Miss E. Feyen

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources